TheraGenetics names Bromley, Milne, to new positions

By Mass High Tech Staff

MIT Enterprise Forum taps Kivel as global chairman [July 9, 2008]

Yale-developed tools fix broken DNA strands [September 2, 2010]

MIT alum’s $4.5M gift forms autism initiative [February 11, 2009]

Yale adds $11M, 5-year grant to AIDS research [September 11, 2008]

TheraGenetics Ltd., a personalized medicine and diagnostics company, reports it has named Susan Bromley its global head of research and development and Kenneth Milne as its U.K. director of R&D.

The two newly created positions at the startup, which has offices in Cambridge, Mass. and London, will help the company move its diagnostic products for use in prescribing central nervous system drugs into clinical practice, said Richard Kivel, CEO of the company.

Bromley was most recently a vice president of diagnostic product development at Xceed Molecular, a Toronto firm with offices in Wellesley. She earned her Ph.D. in biology from Yale University. Milne has worked in various senior roles at British in vitro diagnostics firm Axis-Shield PLC. He has a Ph.D. in biochemistry from the University of Dundee, in Dundee, U.K.

Privately held TheraGenetics says it was spun out of the Institute of Psychiatry at King’s College London in April 2006. Earlier this month, TheraGenetics signed a licensing deal with a renowned Canadian mental health center to expand its portfolio of genetic indicators, which the firm plans to use to develop tests that predict how patients would respond to treatments for central nervous system (CNS) disorders based on their genes.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.